Bhatia AK, et al. – Experts reported long-term results from a phase 3 randomized trial that compared treatment with low-dose 13-CRA versus placebo for patients who had early stage SCCHN, with a focus on the development of second primary tumors (SPTs)and overall survival (OS). As per findings, the incidence of SPT was not decreased by treatment with low–dose 13–Cis retinoic acid (13–CRA) for 2 years. Among patients who were women and never/former smokers, there appeared a potential survival advantage.